Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Heron Therapeutics Inc (HRTX) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs Heron Therapeutics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $20.18, while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). Which is the better fit depends on your goals.

CONYHRTX
Sector
Income / Options OverlayHealth
52-Week High
$103.20$2.04
52-Week Low
$18.43$0.39
Market Cap
$82.52M
Enterprise Value
$180.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.

The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX